Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2023-02-23
DOI
10.3389/fonc.2023.1120278
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Regulating Oncogenic LncRNA DANCR with Targeted ECO/siRNA Nanoparticles for Non-Small Cell Lung Cancer Therapy
- (2022) Calin Nicolescu et al. ACS Omega
- Emerging Role of Noncoding RNAs in EGFR TKI-Resistant Lung Cancer
- (2022) Jingwei Li et al. Cancers
- The effectiveness of the Guy’s Rapid Diagnostic Clinic (RDC) in detecting cancer and serious conditions in vague symptom patients
- (2021) Saoirse Olivia Dolly et al. BRITISH JOURNAL OF CANCER
- Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury
- (2021) Tohru Ohmori et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies
- (2021) Raefa Abou Khouzam et al. Frontiers in Immunology
- Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR)
- (2021) Nichole E. M. Kaufman et al. MOLECULES
- Cannabinoids and Eye: Focus on Angiogenesis and Endothelial Cells
- (2021) Amir Hossein Norooznezhad et al. SURVEY OF OPHTHALMOLOGY
- Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy
- (2021) Ping Yang et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges
- (2021) Shu‐Jin Li et al. Cancer Communications
- Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFRL858R/T790M kinase inhibitors
- (2021) Shi Ding et al. BIOORGANIC CHEMISTRY
- B7–H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression
- (2021) Youwei Lu et al. ONCOGENE
- Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
- (2021) Damien Reita et al. Cancers
- Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer
- (2020) Kohsuke Isomoto et al. CLINICAL CANCER RESEARCH
- Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)
- (2020) Xin Li et al. Thoracic Cancer
- Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors
- (2020) Taihei Ono et al. INVESTIGATIONAL NEW DRUGS
- Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
- (2020) Charles Pottier et al. Cancers
- Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer
- (2020) Matthew D. Kerr et al. Expert Opinion on Drug Discovery
- The next tier of EGFR resistance mutations in lung cancer
- (2020) Hannah L. Tumbrink et al. ONCOGENE
- Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
- (2019) Haruhiro Saito et al. LANCET ONCOLOGY
- Multiscale modeling reveals angiogenesis-induced drug resistance in brain tumors and predicts a synergistic drug combination targeting EGFR and VEGFR pathways
- (2019) Weishan Liang et al. BMC BIOINFORMATICS
- Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
- (2019) Santoni-Rugiu et al. Cancers
- Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
- (2019) Alessandro Leonetti et al. BRITISH JOURNAL OF CANCER
- The effect of apatinib combined with chemotherapy or targeted therapy on non‐small cell lung cancer in vitro and vivo
- (2019) Mingtao Liu et al. Thoracic Cancer
- Upregulation of OTUD7B (Cezanne) Promotes Tumor Progression via AKT/VEGF Pathway in Lung Squamous Carcinoma and Adenocarcinoma
- (2019) Dan-dan Lin et al. Frontiers in Oncology
- Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
- (2019) Yukio Hosomi et al. JOURNAL OF CLINICAL ONCOLOGY
- Realgar transforming solution suppresses angiogenesis and tumor growth by inhibiting VEGF receptor 2 signaling in vein endothelial cells
- (2018) Peng Song et al. ARCHIVES OF PHARMACAL RESEARCH
- TargetingHER2Aberrations in Non–Small Cell Lung Cancer with Osimertinib
- (2018) Shengwu Liu et al. CLINICAL CANCER RESEARCH
- KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
- (2018) Marta Román et al. Molecular Cancer
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Common Co-activation of AXL and CDCP1 in EGFR -mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis
- (2018) Niki Karachaliou et al. EBioMedicine
- Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines
- (2018) Yanqiong Chen et al. ANTI-CANCER DRUGS
- Overcoming multidrug resistance through inhalable siRNA nanoparticles-decorated porous microparticles based on supercritical fluid technology
- (2018) Pei-Yao Xu et al. International Journal of Nanomedicine
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
- (2017) Yi-Long Wu et al. LANCET ONCOLOGY
- Reprogramming Tumor-Associated Macrophages To Reverse EGFRT790M Resistance by Dual-Targeting Codelivery of Gefitinib/Vorinostat
- (2017) Huige Peng et al. NANO LETTERS
- Significance of Neutrophil-to-lymphocyte Ratio in Western Advanced EGFR-mutated Non-small Cell Lung Cancer Receiving a Targeted Therapy
- (2017) Fausto Meriggi et al. TUMORI
- Dose dependent effects of cadmium on tumor angiogenesis
- (2017) Tianshu Wei et al. Oncotarget
- Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations
- (2017) Ting Ding et al. Journal of Thoracic Disease
- Significance of Neutrophil-to-lymphocyte Ratio in Western Advanced EGFR-mutated Non-small Cell Lung Cancer Receiving a Targeted Therapy
- (2017) Fausto Meriggi et al. TUMORI JOURNAL
- Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
- (2016) J. M. Kim et al. ANNALS OF ONCOLOGY
- A framework for understanding and targeting residual disease in oncogene-driven solid cancers
- (2016) Trever G Bivona et al. NATURE MEDICINE
- Low Prognostic Nutritional Index Correlates with Worse Survival in Patients with Advanced NSCLC following EGFR-TKIs
- (2016) Jin Sheng et al. PLoS One
- The Non–Small Cell Lung Cancer Immune Contexture. A Major Determinant of Tumor Characteristics and Patient Outcome
- (2015) Romain Remark et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysis
- (2015) Tomohiro F. Nishijima et al. CANCER TREATMENT REVIEWS
- Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors
- (2015) M.G. Dal Bello et al. INTERNATIONAL JOURNAL OF CANCER
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
- (2015) Nan Chen et al. Journal of Thoracic Oncology
- Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells
- (2015) Yongik Lee et al. MOLECULAR CARCINOGENESIS
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- High pretreatment serum C-reactive protein level predicts a poor prognosis for combined small-cell lung cancer
- (2015) Na Shao et al. TUMOR BIOLOGY
- High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib
- (2015) Ondrej Fiala et al. TUMOR BIOLOGY
- Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
- (2015) Yu-Mu Chen et al. PLoS One
- ExtendedRASmutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials
- (2014) M. J. Sorich et al. ANNALS OF ONCOLOGY
- Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment
- (2014) Gui-Nan Lin et al. Asia-Pacific Journal of Clinical Oncology
- Thermosensitive hydrogel used in dual drug delivery system with paclitaxel-loaded micelles for in situ treatment of lung cancer
- (2014) ZhouXue Wu et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor
- (2014) June-Koo Lee et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Maintenance of the nutritional prognostic index predicts survival in patients with unresectable metastatic colorectal cancer
- (2014) Tetsuro Ikeya et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS)
- (2014) Fairooz Kabbinavar et al. Journal of Thoracic Oncology
- Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
- (2014) Takashi Seto et al. LANCET ONCOLOGY
- Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
- (2014) MIN WU et al. Molecular Medicine Reports
- Chronic Inflammation and Cytokines in the Tumor Microenvironment
- (2014) Glauben Landskron et al. Journal of Immunology Research
- A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study†
- (2013) J. G. Aerts et al. ANNALS OF ONCOLOGY
- The Prognostic Nutritional Index Predicts Long-term Outcomes of Gastric Cancer Patients Independent of Tumor Stage
- (2013) Kazuhiro Migita et al. ANNALS OF SURGICAL ONCOLOGY
- Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
- (2013) Y. Huang et al. CANCER RESEARCH
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma
- (2013) Zhou-Hong Yao et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Genetic alterations defining NSCLC subtypes and their therapeutic implications
- (2013) Larissa A. Pikor et al. LUNG CANCER
- Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
- (2013) Hong-bing Liu et al. PLoS One
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- The Effectiveness of Erlotinib Against Brain Metastases in Non-Small Cell Lung Cancer Patients
- (2012) Hao Bai et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI)
- (2012) D J Pinato et al. BRITISH JOURNAL OF CANCER
- Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer
- (2012) De-shen Wang et al. MEDICAL ONCOLOGY
- Combined EGFR and VEGFR versus Single EGFR Signaling Pathways Inhibition Therapy for NSCLC: A Systematic Review and Meta-Analysis
- (2012) Xinji Zhang et al. PLoS One
- HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation
- (2012) Ken Takezawa et al. Cancer Discovery
- EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
- (2011) Hiroyuki Yasuda et al. LANCET ONCOLOGY
- Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
- (2009) J. Veeken et al. CURRENT CANCER DRUG TARGETS
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC
- (2009) N. A. Pennell et al. ONCOLOGIST
- Tissue Inhibitor of Metalloproteinase 3 Suppresses Tumor Angiogenesis in Matrix Metalloproteinase 2-Down-regulated Lung Cancer
- (2008) C. Chetty et al. CANCER RESEARCH
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started